Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore whether endostar combined with IP as treatment could
improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy
regimens